Protagen AG, a leading specialist in the development of novel diagnostic tests and companion diagnostics (CDx) in the autoimmune field, today announced that Dr. Oliver Schacht, CEO of Curetis N.V., Holzgerlingen, has joined the company’s Supervisory Board.
Additionally, Dr. Bernhard Kirschbaum, former Merck Pharma Executive and member of the Protagen Board since 2015, was elected as the new Chairman, taking over the position from Prof. Dr. Axel Kleemann.
Dr. Schacht successfully completed the IPO of Curetis in November last year, and served previously in executive positions at Epigenomics Inc. Seattle WA, USA and Epigenomics AG, Berlin. He is a member of the Executive Board of BioDeutschland and has a proven track record in the diagnostics industry, with a strong network in the international capital markets, business development, and sales. “Protagen has recently launched its first proprietary CE-IVD marked products and the Protagen platform is able to continuously deliver novel, clinically validated biomarkers in a market that is in need of novel content,” said Dr. Schacht. “I look forward to supporting the management team and board in translating their efforts into a sustainable commercial success.”
Stefan Müllner, CEO of Protagen, added: “Having successfully executed two IPOs in the diagnostic field, Oliver Schacht will provide invaluable guidance for an effective and targeted expansion of our business.”
Bernhard Kirschbaum, new Chairman of the Protagen Board, commented: “I would like to welcome Oliver Schacht in his new role. Oliver is a great addition to the Board and will help us to grow the business in the demanding field of autoimmune diagnostics. Having served as Chairman of the Board for the last 15 years, Axel Kleemann was the key person who shaped Protagen. We would like to sincerely thank him for his long standing commitment and guidance and I am truly sad to see him leave.”
Source: Protagen
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
